CA2925402A1 - Methods for treating chronic obstructive pulmonary disease using benralizumab - Google Patents

Methods for treating chronic obstructive pulmonary disease using benralizumab Download PDF

Info

Publication number
CA2925402A1
CA2925402A1 CA2925402A CA2925402A CA2925402A1 CA 2925402 A1 CA2925402 A1 CA 2925402A1 CA 2925402 A CA2925402 A CA 2925402A CA 2925402 A CA2925402 A CA 2925402A CA 2925402 A1 CA2925402 A1 CA 2925402A1
Authority
CA
Canada
Prior art keywords
patient
copd
benralizumab
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2925402A
Other languages
English (en)
French (fr)
Inventor
Rene Van Der Merwe
Christine Ward
Ubaldo Martin
Lorin Roskos
Bing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CA2925402A1 publication Critical patent/CA2925402A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2925402A 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab Abandoned CA2925402A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
CA2925402A1 true CA2925402A1 (en) 2015-04-23

Family

ID=52809872

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925402A Abandoned CA2925402A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Country Status (12)

Country Link
US (4) US20150104447A1 (cg-RX-API-DMAC7.html)
EP (2) EP3485902A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016534996A (cg-RX-API-DMAC7.html)
KR (1) KR20160061352A (cg-RX-API-DMAC7.html)
CN (2) CN105636607A (cg-RX-API-DMAC7.html)
AU (2) AU2014334563A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016008082A2 (cg-RX-API-DMAC7.html)
CA (1) CA2925402A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016004329A (cg-RX-API-DMAC7.html)
RU (1) RU2706729C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201601807XA (cg-RX-API-DMAC7.html)
WO (1) WO2015057668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
AU2020398168A1 (en) * 2019-12-06 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods for treating COPD by administering an IL-33 antagonist
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
CA3223191A1 (en) * 2021-09-03 2023-03-09 University Of Utah Research Foundation Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
CA2704600C (en) * 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
MX376656B (es) * 2007-05-14 2025-03-07 Kyowa Kirin Co Ltd Metodos para reducir niveles de basófilos.
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
WO2012049278A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
RU2578468C2 (ru) * 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
WO2012158954A1 (en) * 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) * 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
AU2014306956B2 (en) * 2013-08-12 2019-11-21 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
SMT202100152T1 (it) * 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Also Published As

Publication number Publication date
SG10201807318RA (en) 2018-09-27
AU2020202333A1 (en) 2020-04-23
EP3485902A1 (en) 2019-05-22
MX2016004329A (es) 2016-11-10
BR112016008082A2 (pt) 2017-10-17
US20170107291A1 (en) 2017-04-20
WO2015057668A1 (en) 2015-04-23
JP2016534996A (ja) 2016-11-10
CN105636607A (zh) 2016-06-01
US20150104447A1 (en) 2015-04-16
MX2019013468A (es) 2020-02-12
RU2016118425A (ru) 2017-11-21
SG11201601807XA (en) 2016-04-28
JP6870037B2 (ja) 2021-05-12
JP2019203009A (ja) 2019-11-28
RU2706729C2 (ru) 2019-11-20
EP3057609A1 (en) 2016-08-24
AU2014334563A1 (en) 2016-04-07
EP3057609A4 (en) 2017-03-22
US20200123262A1 (en) 2020-04-23
KR20160061352A (ko) 2016-05-31
RU2016118425A3 (cg-RX-API-DMAC7.html) 2018-07-19
JP2021107421A (ja) 2021-07-29
CN113230399A (zh) 2021-08-10
US20180291108A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
US20200123262A1 (en) Methods For Treating Chronic Obstructive Pulmonary Disease Using Benralizumab
US20240409626A1 (en) Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab
HK40008332A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
HK1224583A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
US20230348606A1 (en) Methods for treating severe asthma in patients with nasal polyposis
US20210095037A1 (en) Methods for treating late-onset asthma using benralizumab
HK40118225A (zh) 使用贝那利珠单抗治疗增强型患者群体慢性阻塞性肺病的方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220927